Grant of Share Options

RNS Number : 6327Q

Ondine Biomedical Inc.

22 February 2023

 

22 February 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Grant of Share Options

Ondine Biomedical Inc. (AIM: OBI) announces that on 21 February 2023 it granted a total of 300,000 options to subscribe for new common shares in the Company ("Options") to its Non-executive Directors as follows:

Director	Position	Options granted	Exercise price	Total options now held
Jean Charest	Non-executive Chair	50,000	21.5p	100,000
Craig Tooman	Non-executive Director	50,000	21.5p	150,000
Jean Duvall	Non-executive Director	50,000	21.5p	150,000
Mike Farrar	Non-executive Director	50,000	21.5p	50,000
Junaid Bajwa	Non-executive Director	50,000	21.5p	50,000
Simon Sinclair	Non-executive Director	50,000	21.5p	50,000

The Options all have an exercise price of 21.5p, being the closing share price on 8 December 2022 (the "Approval Date"), the day on which the grant of Options was approved by the Board. The Options vest evenly over a period of 4 years, with a quarter vesting on each of the four successive anniversaries of the Approval Date, and can be exercised for a period of five years from the Approval Date.

Following the grant of the Options, the Company has 7,870,000 options to subscribe for new common shares outstanding, which represents 4.04 per cent of the Company's current issued share capital.

The FCA notifications in respect of the above Option grants, made in accordance with the requirements of the UK Market Abuse Regulation, are appended below.

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications	+001 (1) 604 838 2702
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Asha Chotai, Sam Butcher	[phone]
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	[phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1.  Jean Charest 2.  Craig Tooman 3.  Jean Duvall 4.  Mike Farrar 5.  Junaid Bajwa 6.  Simon Sinclair
2.	Reason for the Notification
a)	Position/status	1.  Non-executive Chair (PDMR) 2.  Non-executive Director (PDMR) 3.  Non-executive Director (PDMR) 4.  Non-executive Director (PDMR) 5.  Non-executive Director (PDMR) 6.  Non-executive Director (PDMR)
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ondine Biomedical Inc.
b)	LEI	213800QO681575J97813
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options to subscribe for Common Shares
	Identification code	ISIN: CA68234M2058
b)	Nature of the transaction	Grant of options to subscribe for common shares of no par value
c)	Price(s) and volume(s)	PDMR Price(s) Volume(s) Jean Charest Exercise price of 21.5p per share 50,000 Craig Tooman Exercise price of 21.5p per share 50,000 Jean Duvall Exercise price of 21.5p per share 50,000 Mike Farrar Exercise price of 21.5p per share 50,000 Junaid Bajwa Exercise price of 21.5p per share 50,000 Simon Sinclair Exercise price of 21.5p per share 50,000
d)	Aggregated information: ·Aggregated volume ·Price	N/A
e)	Date of the transaction	21 February 2023
f)	Place of the transaction	Outside a trading venue

 

END

 

 

DSHEAAAFAEFDEAA